{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:34:04Z","timestamp":1761741244621,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2020]]},"DOI":"10.6061\/clinics\/2020\/e1492","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T10:18:25Z","timestamp":1586945905000},"page":"e1492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Apoptosis-related gene expression can predict the response of ovarian cancer cell lines to treatment with recombinant human TRAIL alone or combined with cisplatin"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-9410","authenticated-orcid":false,"given":"Let\u00edcia da Concei\u00e7\u00e3o","family":"Braga","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-0507","authenticated-orcid":false,"given":"Nikole Gontijo","family":"Gon\u00e7ales","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-7232","authenticated-orcid":false,"given":"Rafaela de Souza","family":"Furtado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-6169","authenticated-orcid":false,"given":"Warne Pedro de","family":"Andrade","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-0405","authenticated-orcid":false,"given":"Luciana Maria","family":"Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-7861","authenticated-orcid":false,"given":"Agnaldo Lopes da","family":"Silva Filho","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1","key":"10.6061\/clinics\/2020\/e1492_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics7010012","article-title":"Subtypes of Ovarian Cancer and Ovarian Cancer Screening","volume":"7","author":"Koshiyama","year":"2017","journal-title":"Diagnostics"},{"key":"10.6061\/clinics\/2020\/e1492_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/764323","article-title":"Ovarian cancer","volume":"2014","author":"Song","year":"2014","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1492_bib3","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"author":"INCA - Instituto Nacional de C\u00e2ncer","key":"10.6061\/clinics\/2020\/e1492_bib4"},{"key":"10.6061\/clinics\/2020\/e1492_bib5","first-page":"25","article-title":"Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies","volume":"3","author":"Mantia-Smaldone","year":"2011","journal-title":"Cancer Manag Res"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1492_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/gm177","article-title":"Recent insights into the role of NF-kappaB in ovarian carcinogenesis","volume":"2","author":"Alvero","year":"2010","journal-title":"Genome Med"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1492_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/gyno.2001.6194","article-title":"Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells","volume":"81","author":"Cuello","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.6061\/clinics\/2020\/e1492_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/jca.14519","article-title":"Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells","volume":"7","author":"Huang","year":"2016","journal-title":"J Cancer"},{"key":"10.6061\/clinics\/2020\/e1492_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5416923","article-title":"Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1492_bib10","first-page":"3949","article-title":"Role of YAP in lung cancer resistance to cisplatin","volume":"16","author":"Song","year":"2018","journal-title":"Oncol Lett"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1492_bib11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1590\/1414-431X20133003","article-title":"Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer","volume":"46","author":"Sheng","year":"2013","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1492_bib12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.6061\/clinics\/2020\/e1492_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.468","article-title":"Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation","volume":"5","author":"Kao","year":"2014","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.6061\/clinics\/2020\/e1492_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2011.09.040","article-title":"Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells","volume":"314","author":"Zhao","year":"2012","journal-title":"Cancer Lett"},{"issue":"1","key":"10.6061\/clinics\/2020\/e1492_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2004.04.012","article-title":"Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs","volume":"94","author":"Tomek","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.6061\/clinics\/2020\/e1492_bib16","first-page":"75","article-title":"Targeted ovarian cancer treatment: the TRAILs of resistance","volume":"2","author":"Khaider","year":"2012","journal-title":"Am J Cancer Res"},{"issue":"7-8","key":"10.6061\/clinics\/2020\/e1492_bib17","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.biocel.2007.02.007","article-title":"TRAIL signalling: decisions between life and death","volume":"39","author":"Falschlehner","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1492_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1492_bib19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/bjc.2011.84","article-title":"Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis","volume":"104","author":"Duiker","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1492_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am J Pathol"},{"issue":"1-2","key":"10.6061\/clinics\/2020\/e1492_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000479006","article-title":"Ovarian Cancer: A Heterogeneous Disease","volume":"85","author":"Kossa\u00ef","year":"2018","journal-title":"Pathobiology"},{"issue":"1","key":"10.6061\/clinics\/2020\/e1492_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/medicines5010016","article-title":"Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells","volume":"5","author":"Testa","year":"2018","journal-title":"Medicines"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1492_bib23","first-page":"435","article-title":"The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%","volume":"16","author":"Karbownik","year":"2012","journal-title":"Contemp Oncol"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1492_bib24","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.6061\/clinics\/2020\/e1492_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-2187-8-7","article-title":"TRAF molecules in cell signaling and in human diseases","volume":"8","author":"Xie","year":"2013","journal-title":"J Mol Signal"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1492_bib26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1492_bib27","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1074\/jbc.M311243200","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site","volume":"279","author":"Ruiz de Almod\u00f3var","year":"2004","journal-title":"J Biol Chem"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1492_bib28","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/humrep\/den197","article-title":"The developing human ovary: immunohistochemical analysis of germ-cell-specific VASA protein, BCL-2\/BAX expression balance and apoptosis","volume":"23","author":"Albamonte","year":"2008","journal-title":"Hum Reprod"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1492_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S1676-24442006000400008","article-title":"Express\u00e3o das prote\u00ednas BCL-2 e BAX em tumores astroc\u00edticos humanos","volume":"42","author":"Faria","year":"2006","journal-title":"J Bras Patol Med Lab"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1492_bib30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1593\/neo.121528","article-title":"Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma","volume":"15","author":"Tano","year":"2013","journal-title":"Neoplasia"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1492_bib31","first-page":"1645","article-title":"Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis","volume":"61","author":"Lacour","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"10.6061\/clinics\/2020\/e1492_bib32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.cgt.7700597","article-title":"Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect","volume":"10","author":"Seol","year":"2003","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1492_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1011336726649","article-title":"The potential of TRAIL for cancer chemotherapy","volume":"6","author":"Nagane","year":"2001","journal-title":"Apoptosis"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1492_bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1586\/era.11.108","article-title":"Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer","volume":"11","author":"Amm","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.6061\/clinics\/2020\/e1492_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12935-016-0329-y","article-title":"Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways","volume":"16","author":"Zamanian","year":"2016","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1492_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/(SICI)1098-2264(200004)27:4<345::AID-GCC2>3.0.CO;2-3","article-title":"Isolation and characterization of a novel TP53-inducible gene, TP53TG5, which suppresses growth and shows cell cycle-dependent transition of expression","volume":"27","author":"Isaka","year":"2000","journal-title":"Genes Chromosomes Cancer"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222002964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222002964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:57:44Z","timestamp":1761721064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222002964"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322020000100219&lng=en&nrm=iso","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7061320\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/apoptosis-related-gene-expression-can-predict-the-response-of-ovarian-cancer-cell-lines-to-treatment-with-recombinant-human-trail-alone-or-combined-with-cisplatin\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":36,"alternative-id":["S1807593222002964"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2020\/e1492","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apoptosis-related gene expression can predict the response of ovarian cancer cell lines to treatment with recombinant human TRAIL alone or combined with cisplatin","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2020\/e1492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e1492"}}